

AMENDMENTS TO THE CLAIMS

1. **(Withdrawn; Currently Amended)** An isolated nucleic acid which encodes a polypeptide which comprises an amino acid sequence having at least 87% sequence similarity to the amino acid sequence set forth in SEQ ID NO: 1 or 2 of FIG. 1 or FIG. 2.
2. **(Withdrawn; Currently Amended)** An isolated nucleic acid according to claim 1, wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 1 of FIG. 1.
3. **(Withdrawn; Currently Amended)** An isolated nucleic acid according to claim 1 wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2 of FIG. 2.
4. **(Withdrawn)** An isolated nucleic acid according to claim 1 wherein the polypeptide binds to a UL16 and/or a NKG2D receptor.
5. **(Withdrawn; Currently Amended)** An isolated nucleic acid according to claim 1 having a nucleotide sequence which has least 85% sequence identity with the nucleotide sequence set forth in SEQ ID NO: 3 or 4 of FIG. 3 or FIG. 4.
6. **(Withdrawn; Currently Amended)** An isolated nucleic acid according to claim 1 wherein the isolated nucleic acid hybridises with the nucleic acid sequence set forth in SEQ ID NO: 3 or 4 shown in FIG. 3 or FIG. 4 or the complement thereof under stringent conditions.
7. **(Withdrawn)** An isolated polypeptide encoded by the nucleic acid according to claim 1.
8. **(Withdrawn)** An isolated polypeptide which is a fragment of the isolated polypeptide of claim 7 consisting of at least 110 amino acids and being able to bind to a UL16 and/or a NKG2D receptor.

9. **(Withdrawn)** An isolated polypeptide according to claim 7 conjugated to a functional moiety, wherein the functional moiety is a polypeptide, a non-peptidyl chemical compound, a cell or a virus particle.

10. **(Withdrawn)** An isolated polypeptide according to claim 9 wherein the functional moiety has cytotoxic activity or binding activity.

11. **(Withdrawn)** A recombinant vector comprising a nucleic acid according to claim 1.

12. **(Withdrawn)** A host cell comprising a heterologous nucleic acid according to claim 1.

13. **(Withdrawn)** A host cell according to claim 12 wherein the host cell is a bacterial cell or a eukaryotic cell.

14. **(Withdrawn)** A method of producing a RAET1G polypeptide comprising: (a) causing expression from nucleic acid which encodes a RAET1G polypeptide according to claim 1 in a suitable expression system to produce the RAET1G polypeptide recombinantly; and, (b) testing the recombinantly produced polypeptide for RAET1G activity.

15. **(Withdrawn)** An isolated antibody that binds specifically to a RAET1G polypeptide according to claim 7.

16. **(Previously Presented)** A method of identifying a disease condition in an individual, comprising: determining the presence or amount of RAET1G polypeptide in a sample obtained from the individual.

17. **(Previously Presented)** A method according to claim 16 wherein the condition is a cancer condition.

18. **(Original)** A method according to claim 16 wherein the condition is an inflammatory disease.

19. **(Original)** A method according to claim 18 wherein the inflammatory disease is coeliac disease.

20. **(Original)** A method according to claim 16 wherein the RAET1G polypeptide is soluble.

21. **(Currently Amended)** A method according to claim 20 wherein the soluble RAET1G polypeptide consists of amino acid sequence set forth in SEQ ID NO: 1 of FIG. 1.

22. **(Currently Amended)** A method according to claim 16 wherein the RAET1G polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 2 of FIG. 2.

23. **(Previously Presented)** A method according to claim 16 wherein the presence or amount of the polypeptide is determined by contacting the sample with an antibody.

24. **(Withdrawn)** A method of identifying a disease condition in an individual, comprising: determining the presence or amount of a nucleic acid encoding a RAET1G polypeptide in a sample obtained from the individual.

25. **(Withdrawn)** A method according to claim 24 wherein the condition is a cancer condition.

26. **(Withdrawn)** A method according to claim 24 wherein the condition is an inflammatory disease.

27. **(Withdrawn)** A method according to claim 26 wherein the inflammatory disease is coeliac disease.

28. **(Withdrawn)** A method according to claim 24 wherein the nucleic acid encodes a soluble RAET1G polypeptide.

29. **(Withdrawn; Currently Amended)** A method according to claim 28 wherein the nucleic acid comprises the nucleotide sequence set forth in SEQ ID NO: 4 of FIG. 4.

30. **(Withdrawn)** A method according to 24 wherein the nucleic acid comprises the nucleotide sequence set forth in SEQ ID NO: 3 of FIG. 3.

31. **(Withdrawn)** A method according to claim 17 wherein the sample comprises epithelial and/or epithelially derived cells.

32. **(Withdrawn)** A method according to claim 31 wherein the epithelial or epithelially derived cells are from the kidney, liver, lung, oesophagous, ovary, skin and/or uterus.

33. **(Withdrawn)** A method for obtaining and/or identifying a modulator of a RAET1G polypeptide, which method comprises: (a) bringing into contact a RAET1G polypeptide and a test compound; and (b) determining the interaction of the RAET1G polypeptide with the test compound.

34. **(Withdrawn)** A method for obtaining and/or identifying a compound which modulates the interaction of RAET1G with UL16 and/or NKG2D, which method comprises: (a) bringing into contact a RAET1G polypeptide and a UL16 or NKG2D polypeptide in the presence of a test compound; and (b) determining the interaction between the UL16 or NKG2D polypeptide and the RAET1G polypeptide before and after addition of the test compound.

35. **(Withdrawn)** A method according to claim 33 comprising identifying the test compound as a modulator of RAET1G activity.

36. **(Withdrawn)** A method according to claim 33 comprising isolating and/or purifying a test compound.

37. **(Withdrawn)** A method according to claim 33 comprising synthesising and/or manufacturing said test compound.

38. **(Withdrawn)** A method according to claim 33 comprising modifying the test compound to optimise the pharmaceutical properties thereof.

39. **(Withdrawn)** A method according to claim 33 comprising formulating the test compound in a pharmaceutical composition with a pharmaceutically acceptable excipient, vehicle or carrier.

40. **(Withdrawn; Currently Amended)** A method of producing a pharmaceutical composition comprising formulating an RAET1G polypeptide according to claim 7 or fragment thereof, or nucleic acid which encodes a polypeptide which comprises an amino acid sequence having at least 87% sequence similarity to the amino acid sequence set forth in SEQ ID NO: 1 or 2 of FIG. 1 or FIG. 2 or a fragment thereof, or an antibody that binds specifically to a RAET1G polypeptide in a pharmaceutical composition with a pharmaceutically acceptable excipient, vehicle or carrier.

41. **(Withdrawn)** A modulator of RAET1G activity obtained by a method of claim 33.

42. **(Withdrawn)** A modulator of RAET1G activity according to claim 41 comprising a peptide fragment of a RAET1G polypeptide.

43. **(Withdrawn; Currently Amended)** A method of treating a human or animal in need thereof for a condition mediated by RAET1G, comprising administering a RAET1G polypeptide according to claim 7 or fragment thereof, or nucleic acid which encodes a polypeptide which comprises an amino acid sequence having at least 87% sequence similarity to the amino acid sequence set forth in SEQ ID NO: 1 or 2 of FIG. 1 or FIG. 2 or a fragment thereof, an antibody that binds specifically to a RAET1G polypeptide or a modulator of a RAET1G polypeptide.

44. **(Canceled)**

45. **(Withdrawn)** A method of claim 43, wherein the condition is selected from the group consisting of a pathogenic infection, a cancer condition and an immune disorder.

46.-47. **(Canceled)**